Mass General: Three-Drug Combination Prolongs Survival in Men With Metastatic, Hormone-Sensitive Prostate Cancer
February 21, 2022
February 21, 2022
BOSTON, Massachusetts, Feb. 21 (TNSJou) -- Massachusetts General Hospital issued the following news release:
Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer, a disease that is fatal in most cases. The study, which was conducted by a team le . . .
Results from an international, randomized, double-blind, placebo-controlled, phase 3 clinical trial indicate that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy prolongs the survival of men with metastatic, hormone-sensitive prostate cancer, a disease that is fatal in most cases. The study, which was conducted by a team le . . .